
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.
Under the terms of the revised agreement:
Source:






